NCT05780268: A trial that was reported late by National Institute of Allergy and Infectious Diseases (NIAID)
This trial has reported, although it was 535 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT05780268 |
|---|---|
| Title | A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients With COVID-19 (Trial H1: LY3819253 (LY-CoV555)) |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Aug. 5, 2020 |
| Completion date | Feb. 1, 2021 |
| Required reporting date | Feb. 1, 2022, midnight |
| Actual reporting date | July 21, 2023 |
| Date last checked at ClinicalTrials.gov | March 28, 2025 |
| Days late | 535 |